NGL Fine-Chem Ltd.

₹2,190.4

-79.7 (-3.5%)

NGLFINE Share Price

Pharmaceuticals & Biotechnology

As on February 6, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,334 Cr

P/E Ratio64.8

Dividend Yield0.02 %

Trendline Performance

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	2,037.2	Bullish
10-DMA	1,863.66	Bullish
20-DMA	1,679.52	Bullish
50-DMA	1,478.48	Bullish
100-DMA	1,465.21	Bullish
200-DMA	1,348.5	Bullish

Historical Performance

1 Year

8.9%

3 Years

44.2%

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	3,683	3,387	2,781	3,175	2,580
Total Expenditure	3,335	2,849	2,431	2,493	1,779
Other Income	86	141	55	107	80
Operating Profit	434	679	405	789	881
Interest	33	18	18	19	22
Depreciation	125	116	113	104	83
Profit Before Tax	277	544	274	666	776
Consolidated Net Profit	209	412	204	498	566
Adjusted EPS	34	67	33	81	92

Compounded Sales Growth

10 Years:19.2

5 Years:19.4

3 Years:3

TTM:1.7

Compounded Profit Growth

10 Years:0.7

5 Years:20.8

3 Years:-16

TTM:-12.7

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:13.7

TTM:16.1

Return on Equity

10 Years:N/A

5 Years:91.6

3 Years:33

last year:33.8

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	31	31	31	31	31
Total Reserves	2,793	2,595	2,195	2,001	1,514
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	320	63	62	81	112
Other Current Liabilities	122	40	37	44	61
Short Term Borrowings	478	317	284	234	48
Total Liabilities	4,334	3,555	2,871	2,769	2,074
Capital Work in Progress	497	455	263	64	124
Long Term Loans & Advances	45	72	58	57	64
Currents Investments	597	536	395	287	291
Short Term Loans and Advances	325	211	150	212	140
Total Current Assets	2,354	2,127	1,627	1,735	1,245
Total Assets	4,334	3,555	2,871	2,769	2,074
Adjusted Book Value	457	425	360	329	250

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 64.8, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a moderate 3-year price CAGR of 13.7%, reflecting average market performance.
The stock carries a beta of 1.0, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹434 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹3683 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1160784.3

No. of Shares: 530 (Approx)

Performance:16.1%

P/L: ₹160784.3

NIFTY Performance: 9.1%

1 day Top Gainers